CCRM Australia accelerates the commercialisation of regenerative medicine therapies and related technologies. The company connects stakeholders, provides funding, expertise, and access to cutting-edge facilities to transform ideas into life-changing therapies.

Our vision at CCRM Australia is to enable unique translational platforms that address the key challenges in commercializing regenerative medicine. We seek to integrate Australia's strengths in stem cell and biomaterials science with dynamic business leadership, and to engage with industry partners to create a global nexus of regenerative medicine commercialization. We also aim to internationalize Australian regenerative medicine activities and connect with leading regenerative medicine powerhouses around the world.

Collaborating with CCRM Australia gives you access to world-class expertise in the development and commercialization of regenerative medicine technologies, as well as the opportunity to promote Australia's state-of-the-art discoveries and expertise to a growing international network of industry partners. We also offer support and validation for locally developed intellectual property, and help increase deal flow through strategic alliances with local and international investors.

Our commercially focused solutions enable businesses and research partners to optimise their international objectives by providing customised support in areas such as executive leadership, market awareness, commercialization knowledge, sustainable partnerships, and stakeholder engagement. We aim to enhance skills, knowledge, and capabilities to forge lasting business partnerships and shape the discussion on contemporary developments in the regenerative medicine industry."

Why work with us

In today’s fast-evolving landscape of regenerative medicine, advanced therapeutics, and cell and gene therapies, companies—particularly small to medium-sized enterprises (SMEs)—require more than just technical capability. They need trusted partners who bring deep domain knowledge, commercial acumen, regulatory fluency, and a track record of translating science into scalable, investable ventures.

CCRM Australia offers a uniquely integrated platform that brings all these components together, making it the preferred choice over other organisations in the sector.

1. A Proven and Globally-Connected Model

CCRM Australia operates under the successful Canadian model, adapted to suit the Australian innovation and commercialisation landscape. This model has been tested, refined, and scaled internationally with demonstrable results, particularly through its Canadian counterpart, CCRM (Toronto), which has contributed significantly to the global advanced therapies ecosystem.

By choosing CCRM Australia, companies tap into:

• An international network of expertise, including scientific, commercial, and regulatory partners;
• Established relationships with global industry leaders and investors;
• The credibility of a globally respected brand committed to advancing therapeutics.

This global connectivity is unmatched by most Australian-based competitors and significantly enhances companies' ability to scale beyond local markets.

2. Integrated Support Across the Translational Pipeline

Many competitors offer support only in fragmented or specialised parts of the development pathway (e.g. academic-only, GMP-only, or venture support-only). CCRM Australia and its Network partner offers end-to-end commercialisation support, including:

• Technology and IP evaluation;
• Commercial strategy development;
• Process development and translational science;
• Early-stage GMP manufacturing;
• Regulatory strategy and quality systems;
• Investment-readiness and capital connections;
• Business development and international market access.

This full-service capability ensures that companies are not lost between fragmented service providers, reducing risk, improving efficiency, and accelerating time to market.

3. Commercialisation-Focused Facilities

CCRM Australia is in the process of establishing a state-of-the-art process development and GMP manufacturing facility, specifically tailored for regenerative medicine and cell and gene therapy companies. This facility—unlike academic or generic contract manufacturing organisations (CMOs)—has been designed with commercial readiness, regulatory compliance, and SME accessibility in mind.

Key features include:

• Flexible, scalable manufacturing spaces suitable for early-phase clinical supply;
• Expertise in developing scalable processes to reduce cost-of-goods and improve reproducibility;
• Integration with translational services, providing a seamless path from lab bench to GMP lot.

These purpose-built facilities position CCRM Australia ahead of competitors that may lack either the regulatory sophistication or the infrastructure capacity to meet the needs of commercial-stage ventures.

4. Experienced, Multidisciplinary Leadership

CCRM Australia brings together decades of leadership experience in science, industry, venture building, IP, and government engagement. Led by Silvio Tiziani, who has over 25 years of experience in executive scientific and commercial roles, CCRM Australia’s leadership team understands both the technical and strategic challenges that emerging therapeutics face.

This cross-functional expertise allows CCRM Australia to:

• Anticipate sector trends and policy changes;
• Identify and unlock value in complex technologies;
• Position ventures for local and international investment.

Competitors often lack this blend of technical depth and commercial insight, offering either academic consultancy or limited technical services without a holistic, strategic lens.

5. Access to Funding Pathways and Programs

CCRM Australia supports companies in leveraging public and private investment channels. It:

• Offers mechanisms such as debt-for-equity arrangements and R&D Tax Concession models;
• Connects companies with private venture capital, philanthropic sources, and international investment.

Its involvement in these programs is not just advisory—CCRM Australia often serves as the industry partner and delivery agent, actively driving the project and representing the commercial interests of companies to government and investors.

6. A Collaborative, Not Competitive, Ethos

CCRM Australia is not a competitor to its clients. It does not seek IP ownership or disproportionate commercial returns. Instead, it plays an enabling role, helping ventures mature, de-risk, and succeed. This collaborative ethos ensures that CCRM Australia is a true partner, not a transactional service provider.

Conclusion

CCRM Australia is more than a service provider—it is an ecosystem enabler, a translational engine, and a trusted national asset. Its holistic, mission-aligned, and globally connected model ensures that companies receive not only world-class technical services but also the strategic guidance, partnerships, infrastructure, and capital pathways needed to thrive.

For any company seeking to develop, scale, and commercialise cell and gene therapies or regenerative medicine technologies in Australia, CCRM Australia is the most capable, credible, and committed partner available.